Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06742996
Registration number
NCT06742996
Ethics application status
Date submitted
16/12/2024
Date registered
19/12/2024
Date last updated
29/10/2026
Titles & IDs
Public title
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Query!
Scientific title
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Query!
Additional trial identifiers [1]
0
0
2024-515593-27-00
Query!
Additional trial identifiers [2]
0
0
BGB-11417-302
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Mantle Cell Lymphoma
0
0
Query!
B Cell Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - Sonrotoclax
Treatment: Drugs - Zanubrutinib
Treatment: Drugs - Placebo
Experimental: Arm A: sonrotoclax plus zanubrutinib - Sonrotoclax and zanubrutinib will be administered in combination.
Placebo comparator: Arm B: placebo plus zanubrutinib - Placebo and zanubrutinib will be administered in combination.
Treatment: Drugs: Sonrotoclax
Administered orally
Treatment: Drugs: Zanubrutinib
Administered orally
Treatment: Drugs: Placebo
Administered orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS) as assessed by Blinded Independent Review Committee (BIRC)
Query!
Assessment method [1]
0
0
PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.
Query!
Timepoint [1]
0
0
Approximately 41 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time from randomization to the date of death from any cause.
Query!
Timepoint [1]
0
0
Approximately 92 months
Query!
Secondary outcome [2]
0
0
PFS as assessed by investigator (INV)
Query!
Assessment method [2]
0
0
PFS is defined as the time from randomization to the date of progression or death, whichever occurs first.
Query!
Timepoint [2]
0
0
Approximately 58 months
Query!
Secondary outcome [3]
0
0
Overall Response Rate (ORR) as assessed by BIRC and by INV
Query!
Assessment method [3]
0
0
ORR is defined as the percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR), per Lugano 2014 criteria.
Query!
Timepoint [3]
0
0
Approximately 58 months
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR) as assessed by BIRC and by INV
Query!
Assessment method [4]
0
0
DOR is defined as the time from the first qualifying response to the date of progression or death, whichever occurs first.
Query!
Timepoint [4]
0
0
Approximately 58 months
Query!
Secondary outcome [5]
0
0
Complete Response Rate (CRR) as assessed by BIRC and by INV
Query!
Assessment method [5]
0
0
CRR is defined as the percentage of participants who achieved a best overall response of CR.
Query!
Timepoint [5]
0
0
Approximately 58 months
Query!
Secondary outcome [6]
0
0
Time to first response as assessed by BIRC and by INV
Query!
Assessment method [6]
0
0
Time to first response is defined as time from the date of randomization to first response.
Query!
Timepoint [6]
0
0
Approximately 58 months
Query!
Secondary outcome [7]
0
0
Time to initiation of new anticancer therapy
Query!
Assessment method [7]
0
0
Time to initiation of new anticancer therapy is defined as time from the date of randomization to the date of initiation of new anticancer therapy.
Query!
Timepoint [7]
0
0
Approximately 58 months
Query!
Secondary outcome [8]
0
0
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Non-Hodgkin Lymphoma High Grade Module 29 (EORTC-QLQ-NHL-HG29)
Query!
Assessment method [8]
0
0
Patient-reported symptom burden, neuropathy, and physical condition/fatigue as measured by the EORTC-QLQ-NHL-HG29 questionnaire. The EORTC-QLQ-NHL-HG29 is the NHL-aggressive module of QLQ-C30; and it consists of 5 scales: Symptom burden due to disease and/or treatment (7 items), Neuropathy (2 items), Physical condition/Fatigue (5 items), Emotional impacts (4 items), and Worries/Fears health and functioning (11 items). Items are rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much"). A higher score for all the multi-item scales and items represents a higher level of symptomatology or problems.
Query!
Timepoint [8]
0
0
Approximately 58 months
Query!
Secondary outcome [9]
0
0
Health-Related Quality of Life (HRQoL) as Assessed by the European Organisation of Research and Treatment of Cancer-Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Query!
Assessment method [9]
0
0
Patient-reported global health status (GHS), role, and physical function as measured by the EORTC-QLQ-C30 questionnaire. The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best).
Query!
Timepoint [9]
0
0
Approximately 58 months
Query!
Secondary outcome [10]
0
0
Number of participants with treatment-emergent adverse events (TEAEs)
Query!
Assessment method [10]
0
0
Number of participants with TEAEs, including laboratory values, vital signs, electrocardiogram results, and physical examination findings, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.
Query!
Timepoint [10]
0
0
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 58 months
Query!
Eligibility
Key inclusion criteria
* Histologically locally confirmed diagnosis of MCL based on the World Health Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on International Consensus Classification (ICC)
* Ability to provide archival or fresh tumor tissue for retrospective central confirmation of MCL diagnosis
* Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in the opinion of the investigator
* Relapsed or refractory disease after the last line of therapy
* Measurable disease defined as = 1 nodal lesion that is > 1.5 cm in longest diameter, or = 1 extranodal lesion that is > 1 cm in longest diameter
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
* Adequate organ function
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i)
* Prior therapy with BTK degraders
* Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi) unless the participant was intolerant of non-zanubrutinib covalent or non-covalent BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to failure of BTKi therapy are ineligible.
* Prior autologous stem cell transplantation or chimeric antigen receptor T-cell therapy within 3 months before first dose of study drug
* Prior allogeneic stem cell transplant within 6 months of the first dose of the study drug
* Known central nervous system involvement by lymphoma
* Clinically significant cardiovascular disease
* History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/03/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/03/2032
Query!
Actual
Query!
Sample size
Target
300
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Sunshine Coast Hospital and Health Service - Birtinya
Query!
Recruitment hospital [2]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [3]
0
0
Monash Health - Clayton
Query!
Recruitment hospital [4]
0
0
Rockingham Hospital - Cooloongup
Query!
Recruitment hospital [5]
0
0
Perth Blood Institute - West Perth
Query!
Recruitment postcode(s) [1]
0
0
QLD 4575 - Birtinya
Query!
Recruitment postcode(s) [2]
0
0
VIC 3128 - Box Hill
Query!
Recruitment postcode(s) [3]
0
0
VIC 3168 - Clayton
Query!
Recruitment postcode(s) [4]
0
0
WA 6168 - Cooloongup
Query!
Recruitment postcode(s) [5]
0
0
WA 6005 - West Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Iowa
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Massachusetts
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Minnesota
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Mississippi
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nebraska
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Tennessee
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Texas
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Washington
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Wisconsin
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Caba
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Ciudad Autonoma Buenos Aires
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Córdoba
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Sankt Pölten
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Barretos
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Belo Horizonte
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Campinas
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Caxias do Sul
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
Curitiba
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Joinville
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Porto AlegreRS
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Recife
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
São Paulo
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Vitória
Query!
Country [41]
0
0
China
Query!
State/province [41]
0
0
Beijing Municipality
Query!
Country [42]
0
0
China
Query!
State/province [42]
0
0
Chongqing Municipality
Query!
Country [43]
0
0
China
Query!
State/province [43]
0
0
Guangdong
Query!
Country [44]
0
0
China
Query!
State/province [44]
0
0
Heilongjiang
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Henan
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Hubei
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Jiangsu
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Jiangxi
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Liaoning
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Shaanxi
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Shandong
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Shanghai Municipality
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Sichuan
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Zhejiang
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Montpellier
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Nantes
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
PierreBenite
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Tours
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Chemnitz
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Frankfurt am Main
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Halle
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Mutlangen
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
München
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Siegen
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Stuttgart
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Bologna
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Lecce
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Meldola
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Trieste
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Verona
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Aichi-ken
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Chiba
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Ehime
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Gifu
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Hiroshima
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Hokkaido
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Hyogo
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Kagoshima-ken
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Kanagawa
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Miyagi
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Okayama-ken
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Osaka
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Saitama
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Tokyo
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Yokohama
Query!
Country [86]
0
0
New Zealand
Query!
State/province [86]
0
0
Auckland
Query!
Country [87]
0
0
New Zealand
Query!
State/province [87]
0
0
Christchurch
Query!
Country [88]
0
0
New Zealand
Query!
State/province [88]
0
0
Dunedin
Query!
Country [89]
0
0
New Zealand
Query!
State/province [89]
0
0
Tauranga
Query!
Country [90]
0
0
New Zealand
Query!
State/province [90]
0
0
Wellington
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Krakow
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Lodz
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Lublin
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Skorzewo
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Wroclaw
Query!
Country [96]
0
0
Puerto Rico
Query!
State/province [96]
0
0
San Juan
Query!
Country [97]
0
0
South Korea
Query!
State/province [97]
0
0
Busan Gwang'Yeogsi
Query!
Country [98]
0
0
South Korea
Query!
State/province [98]
0
0
Seoul Teugbyeolsi
Query!
Country [99]
0
0
Spain
Query!
State/province [99]
0
0
Barcelona
Query!
Country [100]
0
0
Spain
Query!
State/province [100]
0
0
Madrid
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Majadahonda
Query!
Country [102]
0
0
Turkey (Türkiye)
Query!
State/province [102]
0
0
Ankara
Query!
Country [103]
0
0
Turkey (Türkiye)
Query!
State/province [103]
0
0
Dokuma
Query!
Country [104]
0
0
Turkey (Türkiye)
Query!
State/province [104]
0
0
Kocaeli
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Birmingham
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Bournemouth
Query!
Country [107]
0
0
United Kingdom
Query!
State/province [107]
0
0
Glasgow
Query!
Country [108]
0
0
United Kingdom
Query!
State/province [108]
0
0
Headington
Query!
Country [109]
0
0
United Kingdom
Query!
State/province [109]
0
0
London
Query!
Country [110]
0
0
United Kingdom
Query!
State/province [110]
0
0
Metropolitan Borough of Wirral
Query!
Country [111]
0
0
United Kingdom
Query!
State/province [111]
0
0
Plymouth
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
BeOne Medicines
Query!
Address
Query!
Country
Query!
Secondary sponsor
Nil
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06742996
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Study Director
Query!
Address
0
0
BeOne Medicines
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Study Director
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1.877.828.5568
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
See plan description
Query!
Available to whom?
See plan description
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://beonemedicines.com/science/clinical-trials/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06742996
Download to PDF